Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
14
17
18
12
11
8
Crecimiento de los Ingresos (YoY)
-18%
-6%
50%
9%
38%
-38%
Costo de los ingresos
6
8
9
6
4
3
Utilidad bruta
7
9
9
6
6
5
Venta, General y Administración
15
16
19
18
17
15
Investigación y Desarrollo
3
3
5
3
2
2
Gastos de Operación
18
19
24
21
20
17
Otras Ingresos (Gastos) No Operativos
0
0
0
1
3
-2
Ingreso antes de impuestos
-10
-11
-15
-15
-9
-15
Gasto por Impuesto a la Renta
--
0
--
--
--
--
Ingreso Neto
-10
-11
-15
-15
-10
-15
Crecimiento de la Utilidad Neta
-9%
-27%
0%
50%
-33%
25%
Acciones en Circulación (Diluidas)
2.61
1.34
0.92
0.86
0.81
0.47
Cambio de Acciones (YoY)
93%
45%
7%
6%
70%
49%
EPS (Diluido)
-4.07
-8.42
-16.43
-17.45
-13.27
-33.14
Crecimiento de EPS
-50%
-49%
-6%
32%
-60%
-13%
Flujo de efectivo libre
-8
-9
-12
-14
-11
-8
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
50%
52.94%
50%
50%
54.54%
62.5%
Margen de operación
-71.42%
-58.82%
-83.33%
-125%
-118.18%
-150%
Margen de beneficio
-71.42%
-64.7%
-83.33%
-125%
-90.9%
-187.5%
Margen de flujo de caja libre
-57.14%
-52.94%
-66.66%
-116.66%
-100%
-100%
EBITDA
-9
-9
-14
-15
-13
-12
Margen de EBITDA
-64.28%
-52.94%
-77.77%
-125%
-118.18%
-150%
D&A para EBITDA
1
1
1
0
0
0
EBIT
-10
-10
-15
-15
-13
-12
Margen de EBIT
-71.42%
-58.82%
-83.33%
-125%
-118.18%
-150%
Tasa de Impuesto Efectiva
--
0%
--
--
--
--
Estadísticas clave
Cierre Anterior
$9.2
Precio de apertura
$9.2
Rango del día
$8.71 - $10.14
Rango de 52 semanas
$2.73 - $12.7
Volumen
228.3K
Volumen promedio
2.1M
EPS (TTM)
-5.57
Rendimiento de dividendos
--
Cap. de mercado
$33.4M
¿Qué es EKSO?
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.